Indeterminate Result of Rifampicin Resistance (rpoB gene)-Introduction

Indeterminate Result of Rifampicin Resistance (rpoB gene)-Introduction, Possible Reasons, Solution, and Keynotes

Introduction

The detection of rifampicin resistance in Mycobacterium tuberculosis is primarily based on identifying mutations in the rpoB gene, which encodes the β-subunit of RNA polymerase. This gene is critical for rifampicin binding, and mutations in its rifampicin resistance-determining region (RRDR) are strongly associated with resistance.

An indeterminate result in rifampicin resistance testing typically indicates that the diagnostic test, such as GeneXpert MTB/RIF or other molecular assays, could not definitively confirm whether the sample contains rifampicin-resistant or susceptible M. tuberculosis. This ambiguity arises from various factors, including:

Low Bacterial Load: Insufficient DNA in the sample for reliable amplification or analysis.
Rare or Novel Mutations: Mutations outside the RRDR or those not well-characterized by the test.
Technical Errors: Issues during sample processing or amplification.
Mixed Infections: Presence of both rifampicin-susceptible and resistant strains in the same sample.

Possible Reasons

Possible reasons for an indeterminate result of rifampicin resistance (rpoB gene) include various technical and biological factors. First, low bacterial load in the sample often leads to insufficient DNA for analysis. Additionally, rare mutations outside the rifampicin resistance-determining region (RRDR) may not be detected by standard molecular assays. Furthermore, mixed infections containing both susceptible and resistant strains can cause ambiguous results. Moreover, degraded DNA from poor sample handling affects test reliability. In some cases, technical issues such as PCR inhibitors or machine errors disrupt the amplification process. However, inadequate sample quantity may also contribute to inconclusive findings. Next, suboptimal testing conditions, like expired reagents, increase the risk of indeterminate outcomes. Lastly, novel or uncommon mutations, which are uncharacterized, can lead to test limitations. Therefore, when an indeterminate result occurs, confirmatory tests like sequencing or phenotypic assays should be performed for clarity.

Solution

To address indeterminate results of rifampicin resistance (rpoB gene), several solutions can be implemented effectively. First, repeating the molecular test with a fresh, high-quality sample is often recommended. Additionally, performing phenotypic drug susceptibility testing (DST) can confirm resistance or susceptibility. Moreover, sequencing the rpoB gene can identify rare or novel mutations outside the RRDR region. In some cases, using an alternative molecular assay with broader detection capabilities may resolve ambiguities. Furthermore, addressing technical issues like optimizing sample preparation can improve test reliability. Next, ensuring proper handling and storage of samples helps preserve DNA quality for accurate testing. If necessary, dual testing with a combination of molecular and phenotypic methods provides a comprehensive analysis. Lastly, consulting with an infectious disease expert ensures the appropriate diagnostic and therapeutic approach. Therefore, these steps collectively reduce uncertainties and enhance the accuracy of rifampicin resistance detection.

Keynotes

Keynotes on Indeterminate Result of Rifampicin Resistance (rpoB Gene):

Firstly, indeterminate results occur when molecular tests cannot confirm rifampicin resistance or susceptibility.
Typically, low bacterial load in the sample leads to insufficient DNA for reliable analysis.
Additionally, mutations outside the rifampicin resistance-determining region (RRDR) may remain undetected by standard assays. Moreover, mixed infections with both susceptible and resistant strains often create ambiguous results.
In some cases, technical issues such as PCR inhibitors or sample degradation affect test outcomes.
Furthermore, rare or novel mutations, uncharacterized by current tests, can contribute to indeterminate findings.
Next, poor sample handling or storage may degrade DNA quality, impacting test reliability.
If unresolved, indeterminate results require confirmation through rpoB gene sequencing or phenotypic drug susceptibility testing. Therefore, combining molecular and phenotypic methods helps clarify ambiguous results.
Lastly, quality control in sample processing ensures more consistent and reliable test outcomes.

universe84a